Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
US9399619B2 · kind B2 · utility
12Cited by
2References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 29, 2012 |
| Grant date | Jul 26, 2016 |
| Priority date | — |
| Expiry date | Sep 14, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions of the invention comprise sulfamoylbenzamide derivative useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.